Manager TitleAgeSince
President 63 27/05/2010
Director TitleAgeSince
Director/Board Member 63 26/03/2010
Director/Board Member 85 01/06/2011
Director/Board Member 79 09/05/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.40% - - 0
-0.81%-0.33%+27.15%+81.12% 55.23B
+2.28%-5.02%+28.53%+67.18% 53.75B
-0.11%+0.86%-15.63%-13.56% 23.48B
-1.58%-5.51%-3.51%+375.36% 22B
+2.49%-0.92%+20.31%-12.15% 19.78B
+0.57%-1.65%+28.52%-33.71% 17.44B
+0.58%-5.88%+16.30%+540.37% 14.66B
+1.16%+0.58%+51.87%+181.96% 14.07B
-5.09%-10.87%+153.11%+272.20% 13.02B
Average -0.05%-1.55%+34.07%+162.09% 25.94B
Weighted average by Cap. +0.26%-0.44%+27.63%+125.21%
Logo TESARO Inc
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Employees
-